$60,000 of QUEST DIAGNOSTICS lobbying was just disclosed, from Q2 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Lobbying related to diagnostics and Medicare reimbursement policy. Lobbying related to diagnostics and Medicare reimbursement policy. federal budget issues"
You can find more data on corporate lobbying on Quiver Quantitative.
DGX Insider Trading Activity
DGX insiders have traded $DGX stock on the open market 19 times in the past 6 months. Of those trades, 0 have been purchases and 19 have been sales.
Here’s a breakdown of recent trading of $DGX stock by insiders over the last 6 months:
- CATHERINE T. DOHERTY (EVP, Regional Businesses) has made 0 purchases and 8 sales selling 33,788 shares for an estimated $6,964,736.
- J. E. DAVIS (CEO and President) has made 0 purchases and 2 sales selling 20,000 shares for an estimated $4,066,600.
- KARTHIK KUPPUSAMY (SVP, Clinical Solutions) has made 0 purchases and 2 sales selling 10,775 shares for an estimated $2,167,772.
- PATRICK PLEWMAN (SVP for Diagnostic Services) has made 0 purchases and 4 sales selling 9,885 shares for an estimated $2,025,173.
- MICHAEL E PREVOZNIK (SVP & General Counsel) has made 0 purchases and 3 sales selling 5,515 shares for an estimated $1,136,514.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
DGX Hedge Fund Activity
We have seen 413 institutional investors add shares of DGX stock to their portfolio, and 421 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS GROUP AG removed 412,114 shares (-37.0%) from their portfolio in Q1 2026, for an estimated $80,766,101
- GOLDMAN SACHS GROUP INC removed 359,969 shares (-21.1%) from their portfolio in Q1 2026, for an estimated $70,546,724
- FIDUCIARY MANAGEMENT INC /WI/ removed 325,935 shares (-31.1%) from their portfolio in Q1 2026, for an estimated $63,876,741
- FREESTONE GROVE PARTNERS LP removed 303,524 shares (-98.2%) from their portfolio in Q1 2026, for an estimated $59,484,633
- M.D. SASS, LLC added 299,459 shares (+inf%) to their portfolio in Q1 2026, for an estimated $58,687,974
- BLACKROCK, INC. removed 286,926 shares (-3.0%) from their portfolio in Q1 2026, for an estimated $56,231,757
- JANE STREET GROUP, LLC removed 286,305 shares (-97.8%) from their portfolio in Q1 2026, for an estimated $56,110,053
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
DGX Analyst Ratings
Wall Street analysts have issued reports on $DGX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Jefferies issued a "Buy" rating on 02/11/2026
To track analyst ratings and price targets for DGX, check out Quiver Quantitative's $DGX forecast page.
DGX Price Targets
Multiple analysts have issued price targets for $DGX recently. We have seen 9 analysts offer price targets for $DGX in the last 6 months, with a median target of $225.0.
Here are some recent targets:
- Eric Coldwell from Baird set a target price of $229.0 on 04/22/2026
- Luke Sergott from Barclays set a target price of $230.0 on 04/22/2026
- David Macdonald from Truist Securities set a target price of $225.0 on 04/22/2026
- Kevin Caliendo from UBS set a target price of $220.0 on 04/22/2026
- Elizabeth Anderson from Evercore ISI Group set a target price of $210.0 on 04/08/2026
- Ann Hynes from Mizuho set a target price of $235.0 on 02/12/2026
- Tycho Peterson from Jefferies set a target price of $220.0 on 02/11/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
